The switch from Epstein-Barr virus (EBV) latent infection to lytic replication is governed by two viral transactivators, Zta and Rta. We previously reported that the EBV protein LF2 binds Rta, inhibits Rta promoter activation, and blocks EBV replication in cells. In addition, LF2 induces SUMO2/3 modification of Rta. We now show that this modification occurs at four lysines within the Rta activation domain (426, 446, 517, and 530) and that sumoylation of Rta is not essential for its repression. Coexpression studies demonstrated that Rta is sequestered to the extranuclear cytoskeleton in the presence of LF2. We mapped the LF2 binding site to Rta amino acids (aa) 476 to 519 and showed that LF2 binding is critical for Rta relocalization and repression. The core of this binding site, Rta aa 500 to 526, confers LF2-mediated relocalization and repression onto the artificial transcription factor GAL4-VP16. Mutational analysis of LF2 provided further evidence that Rta redistribution is essential for repression. Rta localization changes during replication of the LF2-positive P3HR1 genome, but not during replication of the LF2-negative B95-8 genome. BLRF2 protein expression was decreased and delayed in P3HR1 cells compared with B95-8 cells, consistent with reduced Rta activity. By contrast, BMRF1 expression, regulated primarily by Zta, did not differ significantly between the two cell lines. Our results support a model in which LF2 regulates EBV replication by binding to Rta and redistributing it out of the nucleus.
Epstein-Barr virus (EBV), the prototypical gammaherpesvirus, causes infectious mononucleosis in healthy individuals, B-cell lymphoproliferative disease in immunosuppressed individuals, and rarely, B-cell lymphomas, Hodgkin lymphoma, and nasopharyngeal carcinoma in otherwise-healthy persons (45, 65) . Gammaherpesviruses, including EBV and Kaposi's sarcoma-associated herpesvirus (KSHV), differ from other viruses because their associated diseases are not the consequence of virus replication. Instead, EBV-associated malignancies are a by-product of the growth and survival signals triggered by limited viral gene expression that allows EBV to persist in a latent state in infected cells, and hence the human population (44) . Because viral replication is not occurring in most EBV-infected cells, inhibitors of replication are not efficacious in treating infectious mononucleosis or EBV-associated malignancies. On the contrary, activation of EBV replication has been suggested as therapy, because virus replication can directly kill EBV-infected tumor cells, sensitize them to nucleoside analogues, and stimulate immunemediated killing via increased virus antigen expression in tumor cells (21, 22, 55) .
Entry into replication is regulated by the EBV genes BZLF1 and BRLF1, encoding the transcriptional activators Z (Zta) and R (Rta), respectively (44, 53) . Zta and Rta must act in concert for EBV replication to occur: deletion of either BZLF1 or BRLF1 renders the virus incompetent for DNA replication and virion production (20) . Some EBV lytic genes are activated primarily by Rta, others primarily by Zta, and some are synergistically activated by the combined actions of Rta and Zta (13, 20, 24, 27, 37, 43, 48, 49, 53, 60, 64) . A subset of EBV genes is activated by Rta but repressed by Zta (18, 49, 64) . In most EBV-positive cell lines, expression of either Zta or Rta induces the expression of the other protein and disrupts latency (62, 73) . Rta activation of some lytic promoters can be enhanced by coexpression of the BRRF1 gene product (Na) (35) . Rta and Zta expression can be induced by B-cell receptor cross-linking, phorbol esters, butyrate, and ionophores, but the physiological signals responsible for inducing EBV replication are not well defined (12, 52) . In latently infected cells, lytic gene expression is suppressed by extensive methylation of the genome (3, 19, 40, 54) . Preferential binding of Zta to methylated DNA is thought to be important for initiating replication from this epigenetic repressed state (3, 16, 23) .
Rta is a 605-amino-acid (aa) member of the gammaherpesvirus ORF50 family of transcriptional activators, which have no known homology to cell transcription factors. The Rta N terminus contains overlapping dimerization (aa 1 to 232) and DNA binding (aa 1 to 280) domains (50) . The C-terminal activation domain is comprised of an essential acidic activation domain (aa 520 to 605) and an accessory activation domain (aa 416 to 519), which adds activation potential (33, 50) . This accessory domain is required for transactivation in B cells but not in epithelial cells (33) . Rta activates many EBV promoters, including the BALF2, BMRF1, and BMLF1 promoters, through a direct mechanism by binding to Rta response elements (RREs) that conform to the consensus GNCCN 9 GGNG (11, (28) (29) (30) . Other promoters lacking RREs are activated through indirect mechanisms that may involve direct promoter targeting through interactions with cell transcription factors or activation of signaling pathways in the cytoplasm (1, 24, 46, 47, 63, 68) . Rta predominantly localizes to the nucleus (13, 14) , and an Rta nuclear localization signal mutant was defective for activation of the BGLF5 promoter and induction of BALF2 expression (36) .
We discovered that EBV LF2, a gene deleted from the B95-8 reference strain (59, 61) , encodes an Rta binding protein (6) . LF2 was also identified as an IRF7 antagonist in a screen for EBV-encoded inhibitors of interferon signaling (72) . In EBV-infected cells, LF2 associated with Rta and abrogated Rta's ability to induce viral DNA replication (5) . We further demonstrated that LF2 impairs Rta lytic promoter activation and inhibited Rta DNA binding in electrophoretic mobility shift assays. However, the repressive effects of LF2 persisted even when Rta was fused to a heterologous GAL4 DNA binding domain that retained DNA binding activity in the presence of LF2. This suggested that LF2's repressive effects could also act directly on the activation domain. The observation that the small ubiquitin-like modifer (SUMO) is covalently linked to Rta in the presence of LF2 provides a plausible mechanism by which LF2 could modulate Rta activity. SUMO modification of transcription factors frequently results in their repression, through recruitment of histone deacetylases (HDACs) and other repressive complexes (2, 25, 26, 31, 70) . Although sumoylation of Rta lysines 19, 213, and 517 previously had been reported to be essential for activation (10) , we demonstrated that mutation of these residues to arginines, which cannot serve as SUMO acceptors, does not impair activation (5) . Instead, the observed loss of activation seen in the earlier study appears to be due to the K213A mutation, which in addition to preventing sumoylation at that residue disrupts DNA binding (9) . Thus, SUMO modification does not appear to contribute to Rta activation but could mediate LF2 represssion of Rta. In this study we sought to determine the mechanism by which LF2 inhibits Rta activity, beginning with an examination of the role of SUMO modification.
MATERIALS AND METHODS
Cell culture. 293T cells are from a human embryonic kidney cell line. The B95-8 Z-HT (B95/Z-HT) and P3HR1 Z-HT (P3/Z-HT) cells have been described elsewhere (39, 71) . B95/Z-HT pCEP4-GFP and pCEP4-Flag-LF2 cells were derived from B95/Z-HT cells transfected with pCEP4-GFP or pCEP4-Flag-LF2, followed by continuous hygromycin selection. All cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY) or RPMI 1640 medium (Gibco) supplemented with L-glutamine (Gibco), penicillin-streptomycin (Gibco), and 10% fetalplex (Gemini Bio-Products, West Sacramento, CA).
Plasmids. pcDNA3-Rta, dsRed-HA-Rta, pFlag-LF2, pGL3-BALF2, pGL3-BMLF1, and pGL3-BMRF1 have been described previously (5, 6) . The BZLF1 (Ϫ221/ϩ13) and BMRF1 (Ϫ299/ϩ59) promoters were amplified from B95-8 genomic DNA and cloned into the pGL3 promoter vector (Promega, Madison, WI). pCEP4-GFP was described previously (51) , and pCEP4-Flag-LF2 was constructed by cloning 3ϫFlag-LF2 from pFlag-LF2 into the BamHI/SnaBI sites of pCEP4 (Invitrogen, Carlsbad, CA). pcDNA3-His-SUMO3 was constructed by inserting a double-stranded oligo into the KpnI/BamHI sites of pcDNA3-HA-SUMO3 (5), which replaced the hemagglutinin (HA) tag with the 6ϫHis tagcontaining sequence GGTACCATGGGCAGCAGCCATCATCATCATCATC ACGGATCC. pcDNA3-Rta 4KR and pcDNA3-Rta 4KR-AD were constructed from pcDNA3-Rta with QuikChange site-directed mutagenesis (Stratagene, La Jolla, CA) using oligos containing the appropriate point mutations. Single lysine revertant mutants K530, K517, K446, and K426 were constructed from pcDNA3-Rta 4KR-AD. pcDNA3-Rta-V5 was constructed by cloning an oligo encoding the V5 epitope (GTACGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCT CGATTCTACGCGTACCGGTTAGTAATGATCTAG) downstream of the Rta open reading frame in pcDNA3-Rta. pcDNA3-Rta-d476-519-V5 was produced by generating the 476-519 deletion by site overlap extension and cloning it into pcDNA3-Rta-V5. pGAL4-VP16 was constructed by PCR amplifying the VP16 activation domain from pVP16 (Clontech, Mountain View, CA) and cloning it into the MluI and XbaI site of pM (Clontech). GAL4-Rta480-501-VP16, GAL4-Rta500-526-VP16, and GAL4-Rta527-550-VP16 were produced by amplifying the appropriate Rta residues by PCR and inserting the fragments into the EcoRI and MluI sites of pGAL4-VP16. The LF2 deletion series was constructed by site overlap extension using external primers containing gateway recombination sequences (shown in capital letters; GGGGACAACTTTGTAC AAAAAAGTTGGCatggccgaagcttaccccgga and GGGGACAACTTTGTACAA GAAAGTTGGcagagtgccctcggaggctac) and internal primers containing each desired deletion. Final PCR products were cloned into the pDONR223 gateway entry vector by BP recombinase reaction and sequenced. Each mutant was subsequently cloned by LR recombinase into the destination vectors pN-2ϫHA and pDEST-myc-eGFP, which have been described previously (6) .
Antibodies. The following antibodies were used for Western blotting, immunoprecipitations, and immunofluorescence: mouse monoclonal antibodies against HA (16B12; Covance, Emeryville, CA), Flag (M2; Sigma, St. Louis, MO), V5 (V5-10; Sigma), VP16 (1-21; Santa Cruz Biotechnology, Santa Cruz, CA), EBV Rta (8C12; Argene, Varilhes, France), EBV BMRF1 (R3; Millipore, Bedford, MA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 6C5; Millipore), and ␣-tubulin (B-5-1-2; Sigma); goat polyclonal anti-lamin B (C-20; Santa Cruz); rabbit polyclonal anti-BRG1 (H-88; Santa Cruz), and EBV BLRF2 (SLO25-1; a generous gift from George Miller, Yale University School of Medicine, New Haven, CT). A polyclonal anti-LF2 rabbit serum was raised against LF2 aa 26 to 44 and affinity purified (Open Biosystems, Huntsville, AL).
Western blot analysis. Total cell lysates or immunoprecipitated proteins were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membranes, and probed with appropriate antibodies. After extensive washing, horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were applied, and the membrane was washed again and then developed with a chemiluminescence reagent Sumoylation assays. A total of 1.5 g of DNA was transfected with Effectene (Qiagen, Valencia, CA) into 293T cells at 50% confluence in six-well plates. The sumoylation assay was performed as described elsewhere (38, 69) . Briefly, after 48 h, the cells were washed and resuspended with ice-cold phosphate-buffered saline (PBS). A fraction was taken and prepared as total cell lysate (input). Remaining cells were lysed in lysis buffer (6 M guanidinium-HCl, 100 mM sodium phosphate buffer [pH 8.0], 10 mM 2-mercaptoethanol) containing 5 mM imidazole and sonicated. His-SUMO-modified proteins were purified by nickel affinity chromatography using nickel-nitrilotriacetic acid (NTA) agarose (Qiagen). The agarose was incubated with the lysates for 2 h at 25°C, washed with lysis buffer and 8 M urea wash buffers (8 M Reporter assays. A total of 1.3 g of DNA was transfected with Effectene (Qiagen) into 293T cells. After 48 h, cells were lysed in reporter lysis buffer (Promega) and clarified by centrifugation. Luciferase (Luciferase assay system; Promega) and ␤-galactosidase (Galacto-Light Plus system; Applied Biosystems, Bedford, MA) activities were measured using an Optocomp I luminometer (MGM Instruments, Hamden, CT). Luciferase assay results were corrected for transfection efficiency based on ␤-galactosidase activity.
Immunofluorescence analysis. 293T cells were grown on glass coverslips coated with poly-D-lysine (BD Biosciences, San Jose, CA), and 0.5 to 1.0 g of total DNA was transfected with Effectene. After 48 h, cells were subjected to Draq5 (Biostatus Limited, Shepshed, United Kingdom) DNA staining, fixed with 1% (wt/vol) paraformaldehyde in PBS, and permeabilized with 0.1% (vol/vol) Triton X-100 in PBS containing 1 mM glycine. Cells were blocked with 5% serum 
RESULTS

Sumoylation of Rta is not required for LF2 repression.
To determine whether LF2-induced sumoylation of Rta is required for inhibition of transactivation, Rta residues that become SUMO modified in the presence of LF2 were identified by using a candidate lysine approach. We previously demonstrated that lysines 19, 213, and 517, which are reported to be SUMO modified (10), are not essential for LF2 repression.
The SUMOplot algorithm (Abgent, San Diego, CA) predicts lysine 316 as the most probable SUMO acceptor site within Rta. To address the possibility that Rta might be SUMO modified at any or all of these residues, lysine 316 was mutated to an arginine in combination with lysines 19, 213, and 517 (Rta 4KR). SUMO modification assays were performed by transfecting Rta or Rta mutants into 293T cells along with Histagged SUMO3, with or without Flag-tagged LF2. SUMOmodified proteins were purified by performing His pull-down assays under denaturing conditions, which abrogated noncovalent protein interactions and inactivated SUMO proteases (69) . When LF2 was cotransfected with His-SUMO3 and Rta or Rta 4KR, higher-molecular-weight Rta species were specifically pulled down (Fig. 1A) . These modified Rta forms were dependent on the presence of both His-SUMO3 and LF2, consistent with SUMO3 modification of Rta and Rta 4KR. This confirms the previously published result that LF2 promotes sumoylation of Rta (5) and demonstrates that this sumoylation is not significantly reduced by the 4KR mutations.
The above results argue that LF2-induced Rta sumoylation must occur at lysines not previously reported or predicted to be SUMO modified. Of the 31 lysines within Rta, only 4 are present within the activation domain. We considered these to be likely candidates for SUMO modification because the Rta activation domain fused to the GAL4 DNA binding domain is susceptible to LF2 repression (5) . Indeed, mutation of these four lysine residues, 426, 446, 517, and 530, to arginines (Rta 4KR-AD) resulted in the complete loss of Rta sumoylation ( Fig. 1A) . Flag-LF2 was pulled down with His-SUMO3, which confirmed that LF2 itself is SUMO modified under these conditions and served as an internal control to demonstrate the consistency among His pull-down assays.
To determine which of the four lysine residues is targeted for sumoylation by LF2, four single lysine revertant mutants of Rta 4KR-AD were made (K426, K446, K517, and K530) and tested for sumoylation as described above (Fig. 1B) . These assays revealed that any of these four lysine residues could serve as a SUMO acceptor site but that lysine 426 appeared to be the preferred residue for sumoylation. The limited ability of lysine 517 to serve as a SUMO acceptor is consistent with the insignificant decrease in sumoylation seen with the original Rta 4KR mutant.
In luciferase reporter gene assays, Rta 4KR-AD activated the BALF2 promoter about 35-fold, comparable to the 50-fold activation seen with wild-type Rta (Fig. 1C) . LF2 cotransfection completely abrogated the ability of Rta as well as that of Rta 4KR-AD to transactivate the BALF2 promoter. Because Rta 4KR-AD is not SUMO modified in the presence of LF2 but is repressed to the same extent as wild-type Rta under the conditions tested, we conclude that Rta sumoylation is not essential for LF2-mediated repression.
LF2 redistributes Rta out of the nucleus to the cytoskeleton. A notable feature of the LF2-Rta interaction is that Rta protein levels become substantially increased in the presence of LF2, despite reduced Rta activity. This does not appear to be due to LF2 transcriptional activation of the cytomegalovirus (CMV) promoter, because LF2 does not exert this effect on CMV-driven reporter genes or on other proteins expressed from the same pcDNA3 vector used to express Rta (data not shown). Although SUMO modification may enhance Rta protein stability, the Rta 4KR-AD experiments described above argue that sumoylation is not required for Rta protein levels to increase in the presence of LF2 (Fig. 1C) . Rather, the accumulation of Rta induced by LF2 appears to correlate with Rta repression. Indeed, transcription factor degradation and activation are reported to be functionally linked (56, 66) . For example, when transcription factors are sequestered into nuclear domain 10 (PML) bodies, their protein levels are frequently increased (57, 74) . We sought to determine if LF2 relocalization of Rta into one of these transcriptionally inactive sites might be the cause of Rta repression and protein accumulation.
To assess whether LF2 affects Rta localization, we expressed Rta and Flag-tagged LF2 alone and in combination in 293T cells and performed crude cytoplasmic-nuclear fractionations based on the method of Dignam et al. (17) . Western blotting confirmed that ␣-tubulin, a cytoplasmic protein, was predominantly in the supernatant and that lamin B, a nuclear protein, localized to the pellet ( Fig. 2A, panel i) . Western blotting revealed that the majorities of Rta and LF2 were in the pellet. Therefore, this crude nuclear fraction was further extracted into NP-40-soluble and -insoluble fractions. As expected, lamin B, a component of the nuclear matrix, was predominantly found in the NP-40-insoluble fraction ( Fig. 2A, panel ii) . Western blotting for Flag demonstrated that LF2 was always found in the NP-40-insoluble component of the crude nuclear fraction. Rta, when expressed alone, was distributed approximately equally in the NP-40-soluble and -insoluble fractions, with a small amount present in the cytoplasm. When cotransfected with LF2, however, Rta was completely redistributed into the NP-40-insoluble fraction, suggesting that LF2 sequesters Rta into an NP-40-insoluble compartment, such as the nuclear matrix.
The subcellular localization of Rta in the presence of LF2 was also examined by immunofluorescence microscopy using V5-tagged Rta and Flag-tagged LF2 expressed alone or in combination in 293T cells. Surprisingly, LF2 was detected exclusively in the perinuclear cytoplasm (Fig. 2B) . The cytoplasmic localization was confirmed for untagged LF2 by immunofluorescence (data not shown) and green fluorescent protein (GFP)-tagged LF2 (see Fig. S1 and S2 in the supplemental material). Rta expressed alone was predominantly nuclear. Coexpression of LF2 resulted in a dramatic relocalization of Rta to the cytoplasm (Fig. 2B) . These results confirmed that Rta relocalizes in the presence of LF2 and suggested that Rta exclusion from the nucleus may mediate LF2's repressive effects on Rta.
Because nuclei prepared by the Dignam method frequently have cytoplasmic contamination, we sought to more precisely define the subcellular localization of the LF2-Rta complex. Rta and Flag-LF2 were again expressed alone and in combination in 293T cells. The transfected cells were fractionated into cytoplasm, membrane, nucleoplasm, chromatin-bound, and cytoskeleton fractions by a sequential extraction procedure. Fractions were monitored using control antibodies for proteins of known localizations: ␣-tubulin (cytoplasm), BRG1 (nucleoplasm and chromatin), and lamin B (nuclear matrix/cytoskeleton). LF2 was predominantly detected in the cytoskeletal fraction and was not affected by Rta cotransfection (Fig. 2C) . By contrast, Rta was found mostly in the nucleoplasm when expressed alone but, in the presence of coexpressed LF2, was enriched in the cytoskeletal fraction and depleted from the nucleoplasm. These data and the fluorescence microscopy analysis ( Fig. 2A and B ) (see Fig. S2 in the supplemental material) suggest that exogenously expressed LF2 localizes to a cytoskeletal compartment that appears to be juxtaposed to the nucleus. In the presence of LF2, Rta is substantially excluded from the nucleoplasm and colocalizes with LF2.
LF2 binding to Rta is required for repression and redistribution. To facilitate testing of whether LF2-mediated relocalization is required for Rta repression, the LF2 binding site within Rta was mapped. Our previous data had suggested that the C-terminal 149 aa of the Rta activation domain are required for interaction with LF2 (5). Because this region includes the epitope detected by the 8C12 Rta monoclonal antibody, Rta deletion mutants were constructed with a C-terminal V5 tag to permit Western blotting. As expected, Rta-V5 strongly interacted with Flag-LF2. In contrast, Rta-⌬476-519-V5 was not detected in the Flag immunoprecipitation reaction (Fig. 3A) . Because stringent extraction conditions (1% NP-40 buffer containing 300 mM NaCl) were required to solubilize LF2-Rta complexes, we cannot exclude the possibility of weak residual binding between LF2 and Rta-⌬476-519-V5, as is suggested by the accumulation of this Rta deletion mutant in the presence of LF2. Nevertheless, our data demonstrate that Rta with aa 476 to 519 deleted is highly deficient for LF2 binding.
To determine whether LF2 binding is required for LF2 repression of Rta transactivation, full-length Rta and Rta ⌬476-519 were assessed for BALF2 promoter activation in the absence and presence of LF2. Consistent with previous reports that Rta aa 416 to 519 serve as an accessory activation domain (33) , Rta ⌬476-519 activated less than the full-length protein (Fig. 3B) . Wild-type Rta activation was reduced in the presence of LF2 to background levels, but Rta ⌬476-519 activation was only moderately reduced (about 33%), retaining activation at levels considerably higher than the background.
The effect of LF2 binding on Rta localization was assessed by expressing Rta or Rta ⌬476-519 in the presence or absence of Flag-LF2 in 293T cells and determining their localization by immunofluorescence. In the absence of LF2, both Rta and Rta ⌬476-519 were almost exclusively nuclear (Fig. 3C ). Wild-type Rta was substantially relocalized out of the nucleus in the presence of LF2, whereas Rta ⌬476-519 showed only a modest decrease in nuclear staining with LF2 coexpression (Fig. 3C) . To quantify the effect of LF2 on Rta localization under each condition, at least 100 cells were observed and classified as demonstrating exclusively cytoplasmic, exclusively nuclear, or cytoplasmic and nuclear Rta staining. When LF2 and wild-type Rta were coexpressed, cells exhibiting exclusively nuclear staining were not observed, and only 26% of cells showed any nuclear Rta staining. By contrast, in the presence of LF2, Rta ⌬476-519 nuclear localization was only modestly reduced: 77% of cells showed partial or complete nuclear Rta localization. Thus, an Rta mutant with 44 aa deleted within the accessory activation domain is markedly impaired for LF2 binding, is relocalized to the cytoplasm with substantially lower efficiency, and is resistant to LF2 repression.
Rta aa 500 to 526 are sufficient to confer LF2-mediated redistribution and repression onto an artificial transcription factor. Because Rta ⌬476-519 may have some residual capacity to interact with LF2, we investigated whether this Rta domain is sufficient to mediate LF2 interaction. The ability of Rta residues to confer LF2 repression onto the artificial transcription factor GAL4-VP16, in which the GAL4 DNA binding domain is fused to the VP16 activation domain, was tested. Consistent with our previous report (5), GAL4-VP16 was not repressed by LF2 coexpresssion (Fig. 4A) . Additionally, when Rta aa 480 to 501 or aa 527 to 550 were fused in frame between the GAL4-VP16 DNA binding and activation domains, no LF2 repressive effects were observed. In contrast, fusion of Rta aa 500 to 526 to GAL4-VP16 resulted in a transcription factor whose activity was inhibited by 90% when LF2 was cotransfected. Although the GAL4-VP16 fusion proteins could be detected by immunofluorescence (Fig. 4B) , their expression could not be demonstrated by Western blotting despite robust activity in reporter assays. This is consistent with other reports using GAL4-VP16 fusion proteins (67) . Only the LF2-repressed GAL4-500-526-VP16 accumulated to detectible levels in the presence of LF2, providing further evidence that LF2-mediated repression results in accumulation of the inhibited transactivator.
To investigate whether the LF2 repression was due to relo-calization, GAL4-VP16 by itself or fused to Rta aa 480 to 501, 500 to 526, or 527 to 550 was transiently expressed along with Flag-LF2. Immunofluorescence was performed using VP16 and Flag antibodies. Like Rta, GAL4-500-526-VP16 was cytoplasmic in the presence of Flag-LF2. By contrast, GAL4-VP16 by itself or fused to Rta aa 480 to 501 or 527 to 550 was detected in the nucleus when coexpressed with LF2 (Fig. 4B) . These data suggest that Rta residues within aa 500 to 526 are sufficient to confer LF2-mediated transcriptional repression and redistribution out of the nucleus. LF2 does not inhibit Rta activation of the BZLF1 or BRLF1 immediate-early gene promoters. Our previous data and the above experiments suggest that LF2 inhibits Rta transactivation of lytic promoters that contain RREs, such as the BALF2 promoter (5) . In order to test whether LF2 can affect activation of promoters that lack RREs, reporter assays with the BRLF1 and BZLF1 promoters were performed. In the absence of LF2, Rta activated the BRLF1 promoter (Rp) approximately 20-fold, and coexpression of LF2 did not significantly impair this activation (Fig. 5i) . The BZLF1 promoter (Zp) was activated approximately 25-fold by Rta expression, and coexpression of LF2 resulted in 2-fold further activation (Fig.5ii) . Thus, LF2 relocalization of Rta out of the nucleus does not impair Rp or Zp activation, consistent with induction of cytoplasmic signaling as an important mechanism of Rta upregulation of these immediate-early promoters.
LF2 inhibition of RRE-containing promoters requires direct binding of LF2 to Rta but not Rta sumoylation. In order to test whether effects of the LF2 binding-deficient and sumoylationdeficient Rta mutants observed on BALF2 promoter activation were characteristic of RRE-containing promoters in general, the effects of these mutants were tested on the BMLF1 and BMRF1 promoters. As with the BALF2 promoter, Rta ⌬476-519 activation of the BMLF1 and BMRF1 promoters was approximately half that seen with wild-type Rta and was not decreased by LF2 coexpression (Fig. 6) . Further, Rta ⌬476-519 was expressed at levels comparable to wild-type Rta but accumulated to a lesser extent in the presence of LF2. By contrast, the sumoylation-deficient Rta 4KR-AD mutant was indistinguishable from wild-type Rta in its activation of the BMLF1 and BMRF1 promoters, and this activation was inhibited by LF2 comparably to that seen with wild-type Rta. These data suggest that results obtained with the BALF2 promoter were representative of RRE promoters in general: LF2 binding is essential for inhibition of Rta activation, but sumoylation is not.
LF2 mutants defective for Rta redistribution cannot repress Rta. To define the LF2 domains that confer Rta repression and (Fig. 7A) . None of the other LF2 deletion mutants significantly affected Rtainduced activation of the BALF2 promoter, despite the fact that these deletions were expressed. Subcellular fractionation of 293T cells cotransfected with the HA-tagged LF2 deletions and Rta demonstrated that only LF2 ⌬401-429 resulted in accumulation of Rta in the cytoskeletal fraction, as seen with full-length LF2 (Fig. 7B) . To confirm this correlation of Rta repression and relocalization, dsRedtagged Rta was cotransfected with GFP-tagged LF2 deletions, and the subcellular localizations of Rta and LF2 were examined by fluorescence microscopy. Coexpression of LF2 1-429 or ⌬401-429 resulted in the redistribution of otherwise-nuclear dsRed-Rta (see Fig. S1 in the supplemental material). The redistributed dsRed-Rta localized to a perinuclear ring, while dsRed-Rta in the presence of other LF2 deletion mutants remained exclusively nuclear. Interestingly, although most of the LF2 mutants were defective for repression, they all showed the same juxtanuclear distribution as wild-type LF2 (see Fig.  S1 and S2 in the supplemental material), suggesting that they are not grossly misfolded. Thus, the C-terminal 29 aa of LF2 are dispensable for Rta repression and relocalization, but the Rta binding domain could not be further defined within the first 400 aa of LF2 based on this panel of deletion mutants.
Rta relocalizes to the cytoskeleton during replication of an LF2-positive EBV genome. In order to assess LF2 effects on Rta during replication of the EBV genome, we compared Rta localization in B95-8 cells, which lack LF2, to B95-8 cells stably transfected with LF2 and to P3HR1 cells, which contain an intact LF2 gene. To allow efficient induction of lytic replication, Zta fused to the hydroxytamoxifen-responsive estrogen receptor hormone binding domain (Z-HT) was stably expressed in B95-8 (B95/Z-HT) and P3HR1 (P3/Z-HT) cells. Addition of 4-hydroxy-tamoxifen (4HT) results in nuclear translocation of the otherwise cytoplasmic Z-HT and induces the lytic cascade. For stable expression in B95/Z-HT cells, the episomal pCEP4 vector containing Flag-LF2 or GFP was used. After hygromycin selection, B95/Z-HT cells expressing Flag-LF2 or GFP were induced for lytic replication and subjected to subcellular fractionation at 24 and 72 h after addition of 4HT. LF2 was found predominantly in the cytoskeletal fraction (Fig. 8A) , and its expression increased over time, possibly due to activation of the pCEP4 CMV promoter during EBV replication. Compared to GFP-expressing controls, cytoskeletal-associated Rta increased when LF2 was expressed in B95/Z-HT, albeit to a lesser extent than seen in P3/Z-HT cells. Surprisingly, immunofluorescence microscopy demonstrated that only about 20% of B95/Z-HT cells expressed detectable Flag-LF2, despite continuous culture in hygromycin (see Fig. S3 in the supplemental material). This suggests that the degree of Rta redistribution in response to LF2 may be much greater than that observed, since 80% of fractionated cells did not contain detectable levels of LF2.
Although profiling experiments have demonstrated that LF2 mRNA levels are detectible by 8 h and peak within 12 h of lytic induction, LF2 protein expression levels during replication have never been reported. Preliminary experiments using LF2-specific rabbit sera (see Fig. S4 in the supplemental material) detected a 45-kDa band corresponding to the predicted size of LF2 in P3/Z-HT cells within 48 h of 4-HT addition (Fig. 8B  and C and unpublished observations) . This band was not detected in B95/Z-HT cells. These experiments demonstrated that LF2 is expressed in P3HR1 cells during lytic replication and that LF2 protein levels are increasing during the first 72 h postinduction. We therefore induced P3/Z-HT and B95/Z-HT cells for 24, 48, and 72 h and collected nucleoplasmic, chromatin, and cytoskeletal fractions (Fig. 8C) . As previously found, detection of nuclear/chromatin (BRG1) and cytoskeletal (lamin B) markers was used to monitor subcellular fraction purity. Western blotting revealed that LF2 was enriched in the cytoskeletal fraction of P3/Z-HT cells at 72 h and to a lesser degree at 48 h. LF2 appeared to be predominantly nucleoplasmic at 24 h in P3/Z-HT cells.
Rta protein was detected primarily in the nucleoplasm of P3/Z-HT cells at 24 h. With time, nucleoplasmic Rta levels decreased, and Rta accumulated in the cytoskeleton. By 72 h, Rta was mostly cytoskeletal in the P3/Z-HT cells. Thus, the Rta distribution correlates with LF2 protein expression in P3/Z-HT cells in a temporal and spatial fashion. By contrast, in B95/ Z-HT cells, Rta was detected equally in the nucleoplasmic, chromatin, and cytoskeletal fractions, and this distribution did not change over time. LF2 was absent in all three B95/Z-HT fractions at any time point.
To identify differences in lytic cascade activation, expression of the protein products of the Zta-responsive BMRF1 gene and the Rta-responsive BLRF2 gene were examined. In both P3/Z-HT and B95/Z-HT cells, BMRF1 protein was detectable in the nucleoplasmic and chromatin fractions at 24 h and increased through the 72-h time point. There were no significant differences in the level or distribution of BMRF1 between the two cell lines. By contrast, BLRF2 expression was markedly delayed in P3/Z-HT cells compared to B95/Z-HT cells during replication. In B95/Z-HT cells, the BLRF2 protein was highly expressed in the nucleoplasm and chromatin fractions by 24 h and remained at elevated levels through 72 h. In P3/Z-HT cells, BLRF2 distribution was similar, but expression levels were markedly decreased at the earlier time points and this difference persisted to a lesser degree through 72 h. In summary, proteins encoded by early and late genes are expressed in the presence or absence of LF2. The observation that the Rta-responsive BLRF2 gene product can be expressed at lower levels with delayed kinetics in P3/Z-HT cells suggests that Rta activity is decreased in these cells compared to B95/Z-HT.
DISCUSSION
Data presented here demonstrate that Rta redistributes from the nucleoplasm to the cytoskeleton during EBV replication. This event is mediated by LF2, as coexpression of LF2 (41); NF-B heterodimers are retained in the cytoplasm through masking of their nuclear localization signal by IB proteins (34, 58) ; monoubiquitination promotes cytoplasmic localization of p53 (7, 8) .
Our finding that the sumoylation-deficient Rta mutant 4KR-AD is efficiently repressed and relocalized in the presence of LF2 (Fig. 1C and data not shown) argues that sumoylation is not responsible for Rta redistribution. It is possible that LF2 induces modifications other than sumoylation that play a role in Rta localization. However, these modifications would have to occur within the 27-aa core of the LF2 binding site or be induced by this binding site in both Rta and the unrelated GAL4-VP16 sequence. The GAL4-VP16 experiment also suggests that nuclear localization signal masking is an unlikely mechanism. Thus, we favor a sequestration mechanism. Sequestration is supported by the observation that Rta accumulates in the same subcellular fraction as LF2. Further, sequestration best explains how the core of the LF2 binding site is sufficient to confer relocalization and repression onto the heterologous GAL4-VP16 transcription factor. Additionally, the inability of LF2 to inhibit activation of Zp and Rp, which can be activated without direct binding of Rta to RREs, is consistent with a sequestration mechanism. Although Rta exclusion from the nucleus is clearly sufficient for repression of RRE-containing promoters, an important outstanding question is whether Rta redistribution is essential. The strong correlation of Rta repression and redistribution observed for the LF2 deletion mutants suggests that it is. The proposed sequestration mechanism predicts that LF2 binds to a cell protein in order to tether the Rta-LF2 complex in the cytoskeleton.
Attempts to prove this sequestration mechanism by making specific mutations in LF2 have been hampered by the lack of an LF2 structure or defined subdomains. LF2 is thought to have evolved from the herpesvirus dUTPase gene, which en- codes a protein that folds into a single globular structure (15) . Current threading algorithms (42) using the EBV dUTPase structure as a basis predict folds for only about 25% of the LF2 residues. Consequently, we constructed 50-aa deletions spanning the LF2 protein in an effort to define an LF2 mutant competent for Rta binding that could not relocalize Rta. With the exception of LF2 with the C-terminal 29 aa deleted, all LF2 mutants studied failed to repress or relocalize Rta. While this supports a correlation between repression and relocalization, 50-aa deletions could disrupt the folding of a globular protein like LF2. On the other hand, the LF2 mutants exhibited the same localization as wild-type LF2 (see Fig. S1 in the supplemental material) and only slightly reduced expression levels ( Fig. 7) , suggesting that they are not grossly misfolded. Construction of LF2 mutants that are deficient for specific functions or protein interactions remains an important unresolved problem. By contrast, efforts to map the LF2 binding domain within Rta were highly successful, identifying a 27-aa sequence that is a critical mediator of LF2 effects. This likely reflects the modular architecture of the Rta protein, which has well-delineated DNA binding and transcriptional activation domains. The newly identified LF2 binding site falls within the accessory activation domain and contains a cluster of residues that are highly conserved among Rta homologues of other lymphocryptoviruses (see Fig. S5 in the supplemental material). Secondary structure algorithms predict an ␣-helix within these conserved residues, and it is tempting to view this LF2 binding domain as a rod-like structure that is enveloped by the globular LF2 protein. The fact that the 8C12 monoclonal epitope overlaps with this binding site and can recognize Rta in its native conformation (e.g., immunofluorescence or immunoprecipitation) lends further support to the notion that this binding site is readily accessible on the surface of the Rta protein. LF2 binding has also been mapped to the central inhibitory association domain of IRF7 (aa 285 to 457) (72) . Although limited regions of homology can be identified between these two binding sites, the IRF7 site will need to be more precisely mapped before it can be reliably judged whether LF2 binds to these proteins via the same mechanism.
Our results demonstrate that the Rta activation domain becomes SUMO modified in the presence of LF2. Rta lysine 426 is the predominant SUMO acceptor, but lysines 446, 517, and 530 can also be SUMO modified to a lesser degree. Rta SUMO modification is not required for activation or essential for LF2-mediated repression, but we cannot completely exclude a role for SUMO modification in LF2-mediated effects. For example, sumoylation may be an important means of Rta inactivation if LF2 levels are limiting or Rta sequestration is incomplete. Our studies of P3HR1 cells demonstrated that Rta persists in the nucleoplasm at 72 h, despite substantial redistribution to the cytoskeletal compartment. Whether nucleoplasmic Rta is further inhibited by LF2-induced sumoylation or inhibition of DNA binding, as we have previously observed, is unknown. Introduction of the Rta 4KR-AD mutant into a recombinant EBV genome may uncover a role for Rta sumoylation that is not apparent in transient assays. It is also possible that sumoylation of LF2 is what determines its localization and, indirectly, mediates Rta relocalization. Alternatively, if LF2 is a SUMO E3 ligase or recruits one, other proteins bound by LF2 may become sumolyated. IRF7 is a potential candidate; however, in preliminary experiments SUMO-modified IRF7 levels were not increased by LF2 coexpression. The precise role of LF2 in EBV biology remains uncertain. However, our results may explain why Rta activates promoters through two distinct mechanisms. LF2 sequestration of Rta markedly impairs activation of RRE-containing promoters without significantly affecting activation of promoters that lack RREs. If LF2 is an EBV virion protein, as are its homologues in other gammaherpesviruses (4, 75) , this differential regulation of Rta may play out in the newly infected cell. In this setting, in cells in which the immediate-early promoters are activated, LF2 would prevent EBV replication but allow activation of other promoters through mechanisms that do not involve Rta binding to RREs (32) . LF2 is unlikely to accomplish this feat alone, as "abortive" lytic replication has been observed in experiments with LF2-negative B95-8 genomes (40) . In those experiments, the unmethylated state of the newly delivered EBV genome was proposed to prevent activation of replication by Zta. It is also probable that LF2's ability to inhibit IRF7 signaling is most important during initial infection. Thus, the inclusion of LF2 into the EBV tegument could foster the establishment of latent infection and allow activation of a subset of Rta-responsive promoters, while simultaneously subverting the cell's innate immune response.
Our current results suggest an important role for LF2 in cells undergoing EBV replication as well. Although LF2 can abrogate EBV replication when transfected into EBV-positive cells (5) , this activity must be regulated for EBV to be able to reproduce itself. Data presented here clearly demonstrate that despite LF2 expression and Rta relocalization in P3HR1 cells, both early and late gene expression proceeds. It is likely that the lower levels of LF2 expression directed by its endogenous promoter temper the ability of LF2 to block replication. LF2 levels may accumulate during replication to some threshold level and serve as a feedback mechanism to force the cell to exit replication and, potentially, to survive. LF2 could also define an upper limit for lytic gene product expression that might otherwise reach toxic levels. The EBV SM protein may also act in this fashion, by limiting the feed-forward activation of Rta on its own promoter (71) . Alternatively, LF2 may be required to balance the expression of lytic genes controlled by Rta with those regulated by Zta. Our results show that BMRF1 expression, driven by the combined effects of ectopic Z-HT and endogenous Zta, is similar in induced B95/Z-HT and P3/ Z-HT cells. In contrast, BLRF2 is markedly less well expressed in P3/Z-HT cells. Although Zta has been reported to repress BLRF2 expression, differences in Zta activity seem unlikely in view of the BMRF1 data. Instead, the decrease in BLRF2 levels in P3/Z-HT is probably due to reduced Rta activity. This did not appear to be due to differences in Rta expression, but we cannot exclude unmeasured effects, such as differences in BRRF1 (Na) coactivation of Rta. To control for these possibilities, an EBV genome selectively deleted for the LF2 open reading frame is being constructed which should allow the effects of LF2 to be studied in an isogenic background. Nevertheless, the observation that Rta is redistributed during EBV replication of the P3HR1 genome, but not the B95-8 genome, implicates LF2 in the observed differences in BLRF2 expression and, by extension, in regulation of lytic replication.
